A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice
Mascola John R. 1Alam Munir 2Wiehe Kevin 2Haynes Barton F. 2Baric Ralph S. 3Gobeil Sophie 2Li Dapeng 2Lu Xiaozhi 2Manne Kartik 2Mansouri Katayoun 2Montgomery Stephanie A. 4Montefiori David. C. 5Graham Barney S. 1Kwong Peter D. 1De la Cruz Gabriela 6Schaefer Alexandra 3Shen Shaunna 5Sempowski Gregory D. 2Anasti Kara 2Acharya Priyamvada 7Zhou Tongqing 1Yount Boyd 3Martinez David R. 3Parks Robert 2Edwards Robert J. 2Barr Maggie 2Saunders Kevin O.7
作者信息
- 1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH
- 2. Duke Human Vaccine Institute, Duke University School of Medicine
- 3. Department of Epidemiology, University of North Carolina at Chapel Hill
- 4. Department of Laboratory Medicine and Pathology, University of North Carolina School of Medicine
- 5. Department of Surgery, Duke University School of Medicine
- 6. Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- 7. Duke Human Vaccine Institute, Duke University School of Medicine||Department of Surgery, Duke University School of Medicine
- 折叠
Abstract
Abstract
SARS-CoV in 2003, SARS-CoV-2 in 2019, and SARS-CoV-2 variants of concern (VOC) can cause deadly infections, underlining the importance of developing broadly effective countermeasures against Group 2B Sarbecoviruses, which could be key in the rapid prevention and mitigation of future zoonotic events. Here, we demonstrate the neutralization of SARS-CoV, bat CoVs WIV-1 and RsSHC014, and SARS-CoV-2 variants D614G, B.1.1.7, B.1.429, B1.351 by a receptor-binding domain (RBD)-specific antibody DH1047. Prophylactic and therapeutic treatment with DH1047 demonstrated protection against SARS-CoV, WIV-1, RsSHC014, and SARS-CoV-2 B1.351infection in mice. Binding and structural analysis showed high affinity binding of DH1047 to an epitope that is highly conserved among Sarbecoviruses. We conclude that DH1047 is a broadly neutralizing and protective antibody that can prevent infection and mitigate outbreaks caused by SARS-like strains and SARS-CoV-2 variants. Our results argue that the RBD conserved epitope bound by DH1047 is a rational target for pan Group 2B coronavirus vaccines.Key words
SARS-CoV-2 D614G/B.1.1.7/B.1.429/B1.351/SARS-like virus/Sarbecovirus/countermeasures/DH1047 antibody/bNAb/panCoV引用本文复制引用
Mascola John R.,Alam Munir,Wiehe Kevin,Haynes Barton F.,Baric Ralph S.,Gobeil Sophie,Li Dapeng,Lu Xiaozhi,Manne Kartik,Mansouri Katayoun,Montgomery Stephanie A.,Montefiori David. C.,Graham Barney S.,Kwong Peter D.,De la Cruz Gabriela,Schaefer Alexandra,Shen Shaunna,Sempowski Gregory D.,Anasti Kara,Acharya Priyamvada,Zhou Tongqing,Yount Boyd,Martinez David R.,Parks Robert,Edwards Robert J.,Barr Maggie,Saunders Kevin O..A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice[EB/OL].(2025-03-28)[2026-05-01].https://www.biorxiv.org/content/10.1101/2021.04.27.441655.学科分类
医学研究方法/基础医学/生物科学研究方法、生物科学研究技术
评论